We showed that the best‐in‐class CFTR modulator Elexacaftor/tezacaftor/ivacaftor is unable to rescue CFTR function in neutrophilic asthma hBECs, because this drug combination works by improving folding, trafficking and membrane openness of a mutated CFTR ion channel in CF, but it is not efficacious in CF patients where there is a lack of CFTR expression. This evidence concerns the gene CFTR and cystic fibrosis.